AbbVie. has filed a patent for a process to prepare a specific compound used in the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. The patent also covers the solid state forms of the compound, pharmaceutical compositions, synthesis methods, and products-by-process. GlobalData’s report on AbbVie gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AbbVie, Peptide pharmacophores was a key innovation area identified from patents. AbbVie's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
The patent filed is for a process to prepare a pharmaceutical composition for treating arthritis
A recently filed patent (Publication Number: US20230312594A1) describes a method for treating active psoriatic arthritis in human patients. The method involves orally administering a tablet once daily to the patient, containing a specific compound called (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1). The tablet should contain a therapeutically effective amount of 15 mg of Compound 1.
The method is specifically targeted towards adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs, methotrexate, or an anti-TNF biologic agent.
The patent also claims that the method results in a specific response called ACR70 at 12 weeks after the first daily administration. ACR70 refers to a 70% improvement in the American College of Rheumatology criteria for assessing disease activity in rheumatoid arthritis.
Additionally, the patent describes similar methods that result in ACR50 and ACR20 responses at 12 weeks after the first daily administration. ACR50 and ACR20 refer to 50% and 20% improvements, respectively, in the American College of Rheumatology criteria for assessing disease activity.
The therapeutically effective amount of Compound 1 in these methods is administered as 15.4 mg of Freebase Hydrate Form C.
Overall, this patent presents a method for treating active psoriatic arthritis in adult patients who have not responded well to other treatments. The method involves orally administering a tablet containing a specific compound, resulting in significant improvements in disease activity as measured by ACR criteria.
To know more about GlobalData’s detailed insights on AbbVie, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
